Tenth Of Ramadan Pharmaceutical Industries&Diagnostic (Rameda) News - Mubasher Info
KSA
Mubasher TV
 Contact Us Advertising   العربية
KSA
TDWL Closed
07 May 03:05 AM

Tenth Of Ramadan Pharmaceutical Industries&Diagnostic (RMDA)

Last update: 2 May 01:29 PM market time.
2.06
0.01
0.49%
Open 2.06
Previous Close 2.06
High 2.10
Low 2.01
Stock Statistics
Volume 5,215,029
Turnover 10,744,525.00
All data are 15 minutes late during market session

News

Photo Archive
8 January 2023 03:12 PM Rameda’s shareholders nod to capital raise
Cairo – Mubasher: The shareholders of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) agreed to increase the company’s issued capital to EGP 252.11 million from EGP 250 million. In order to carry out the capital …
General Assembly
Photo Archive
15 September 2022 11:19 AM Ekuity increases stake in Rameda for EGP 159m
Cairo – Mubasher: Ekuity B.V. bought 53.76 million shares in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) for a total value of EGP 159.52 million, equivalent to an average share price of EGP 2.96. Accordingly, …
Mergers and Acquisitions
Photo Archive
14 September 2022 11:29 AM Rameda sees EGP 144m block trading deal
Cairo – Mubasher: The Egyptian Exchange (EGX) announced a block trading deal worth EGP 144.41 million on the shares of the Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda). The transaction was executed on 48.13 …
Companies Investments
Photo Archive
26 April 2022 03:40 PM Saudi PIF-owned firm raises stake in Egypt’s Rameda
Cairo - Mubasher: Saudi Seventh Investment Company, a subsidiary of the Public Investment Fund (PIF), has increased its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) from 4.51% to 11.01%. The Saudi …
Trading Activities
The compny’s issued and paid-up capital will be increased by EGP 57.850 million
22 September 2021 11:10 AM EGX approves listing Rameda's capital raise shares
Cairo – Mubasher: The Egyptian Exchange's (EGX) listing committee approved listing the capital raise shares of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda).  The company's issued and paid-up capital will be …
Corporate Actions
Revenues soared to EGP 537.77 million in H1-21
9 August 2021 02:49 PM Rameda records EGP 61.5m profits in H1-21
Cairo - Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) achieved a 41.4% annual increase in net profits to EGP 61.47 million in the first half (H1) of 2021 from EGP 43.47 million in H1-20. Revenues soared …
Financial Results
The transaction involved the purchase of 20.83 million shares
29 July 2021 00:31 PM Equinox Pharma ups stake in Rameda for EGP 58.5m
Cairo - Mubasher: Equinox Pharma Holding Limited raised its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) to 15.39% from 12.68%. The transaction involved the purchase of 20.83 million shares for …
Insider Trading & Treasury Stocks
The deal is Rameda's largest acquisition to date
15 July 2021 01:37 PM Rameda acquires anticoagulant molecule
Cairo - Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has acquired an anticoagulant molecule as part of its strategy to scale up its portfolio through purchasing existing molecules with an established …
Companies Investments
The company will distribute 0.30 bonus share for every original share
19 April 2021 11:22 AM Rameda's shareholders approve capital raise via bonus issue
Cairo – Mubasher: The ordinary general meeting (OGM) of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) approved the board’s proposal to distribute bonus shares worth EGP 57.8 million to shareholders for 2020. The …
General Assembly
Revenues rose to EGP 960.16 million last year
2 March 2021 11:16 AM Rameda's profit up 36.5% in 2020 on higher revenue; bonus issue proposed
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) posted net profits of EGP 111.51 million in 2020, up by 36.5% year-on-year (YoY) from EGP 81.67 million, including minority shareholders’ rights. The …
Financial Results
Galxo Group Limited decided to focus on talks with Hikma Pharmaceuticals
9 February 2021 01:27 PM Rameda retracts offer to acquire GSK Egypt
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) retracted its offer to acquire the shares of Galxo Group Limited in Glaxo SmithKline (GSK Egypt), according to a bourse disclosure on Tuesday. This …
Mergers and Acquisitions
Glaxo Group Limited considers to sell its entire stake of 91.2% in GSK Egypt
8 February 2021 04:36 PM Galxo Group rejects talks with Rameda, ACDIMA over potential acquisition
Cairo – Mubasher: Glaxo SmithKline (GSK Egypt) said that its majority shareholder, Galxo Group Limited, responded to the letters of Arab Company for Drug Industries & Medical Appliances (ACDIMA) and the Tenth of Ramadan for Pharmaceutical …
Mergers and Acquisitions
Revenues grew to EGP 672.858 million in the January-September period
10 November 2020 01:26 PM Rameda’s profit jumps 119% in 9M
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) registered a 119% year-on-year (YoY) surge in its net profits, logging EGP 68.16 million in the first nine months of 2020, compared to EGP 31.14 …
Financial Results
The transaction involved 405.36 million shares
1 September 2020 03:43 PM Rameda sees EGP 1.6bn block-trading deal on Tuesday
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) witnessed a block-trading deal worth EGP 1.657 billion on the Egyptian Exchange (EGX). The transaction involved 405.36 million shares, according to a …
Insider Trading & Treasury Stocks
Rameda’s revenues grew to EGP 437.46 million
16 August 2020 00:24 PM Rameda’s profit hikes 111% in H1-20
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) reported a 111% year-on-year (YoY) increase in its net profits to EGP 43.47 million during the first half (H1) of 2020, compared to EGP 20.6 million. …
Financial Results
The first production of Remdisivir is expected to be in September
21 July 2020 01:06 PM Rameda announces prices of COVID-19 medicines
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) announced that the Egyptian Drug Authority (EDA) decided that its Anvirizam drug for coronavirus (COVID-19) treatment will be sold to the public for …
Company News
The medicine will be sold at hospitals only
25 June 2020 11:31 AM Rameda receives export orders for COVID-19 drug Anviziram
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has received several orders from Saudi Arabia, Kuwait, Iraq, and Yemen for the purchase of the antiviral Anviziram for treatment of coronavirus …
Companies Investments
Rameda has also obtained approval to manufacture Remedisivir
23 June 2020 10:54 AM Rameda starts manufacturing Anviziram for COVID-19 treatment
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has started manufacturing the antiviral Anviziram to treat coronavirus (COVID-19) patients. “Anviziram contains the active pharmaceutical ingredient …
Company News
Revenues levelled up to EGP 232.419 million
18 May 2020 11:17 AM Rameda’s profit surges 185% in Q1-20 on higher revenue
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) reported a 185% year-on-year (YoY) leap in its consolidated profits during the first quarter of 2020. The company’s net profits hiked to EGP 23.76 …
Financial Results
The transaction involved 3.57 million shares
18 March 2020 02:31 PM Rameda sees EGP 14m block trading deal
Cairo – Mubasher: The Egyptian Exchange (EGX) executed a block trading deal on the shares of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) at a value of EGP 13.89 million. The transaction involved 3.57 million …
Trading Activities
Rameda’s net profits plunged to EGP 81.67 million
18 February 2020 03:56 PM Rameda’s profit drops 37% in 2019
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) reported a 37% year-on-year profit decline during 2019, the company’s consolidated financial statements showed. Rameda’s net profits plunged to EGP …
Financial Results
he transaction was carried out on 13.379 million shares.
13 February 2020 04:05 PM Rameda executes EGP 62m greenshoe option
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has purchased 13.379 million price stabilisation shares, valued at EGP 62.346 million, the Egyptian Exchange (EGX) said on Thursday. In December …
Trading Activities
Rameda’s stock started trading on the EGX on 11 December
26 January 2020 02:16 PM Rameda's revenue rises to EGP 890m in 2019 unaudited financials
Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) expects generating earnings before interest, taxes, depreciation, and amortisation (EBITDA) of EGP 255 million in 2019, up by 11.7% year-on-year from …
Financial Results
Fawry’s IPO led the 2019 offerings
26 December 2019 02:19 PM EGX sees EGP 5.1bn offerings in 2019
By: Heba El-Kordy Cairo – Mubasher: The Egyptian Exchange (EGX) has witnessed four initial and secondary public offerings during 2019. The EGX hosted the offerings of Eastern Co, Speed Medical Co, Fawry for Banking Technology and Electronic …
Company News
The public offering included 18.8 million shares
8 December 2019 03:49 PM Rameda raises EGP 1.75bn in IPO
Cairo – Mubasher: The public and private offerings of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) have been executed on 376.6 million shares, representing 48.99% of the company’s capital shares, at EGP 4.66 per …
Initial Public Offerings